IN‐VIVO METABOLITES OF SPIRONOLACTONE AND POTASSIUM CANRENOATE: DETERMINATION OF POTENTIAL ANTI‐ANDROGENIC ACTIVITY BY A MOUSE KIDNEY CYTOSOL RECEPTOR ASSAY
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
SUMMARY: We have established a sensitive and specific radioreceptor assay for androgen receptor active materials in plasma, using tritiated methyltrienolone ([3 H]R 1881) as tracer, and spayed mouse kidney cytosol receptor as the binding species. On radioreceptor assay, plasma from mice chronically administered spironolactone contained ˜ 10 times higher levels of androgen receptor active material than from mice administered potassium canrenoate. In parallel bioassays (antagonism of the effect of testosterone on seminal vesicle weight), spironolactone was >4 times as potent an antiandrogen as potassium canrenoate. Administered potassium canrenoate circulates as canrenoic acid, in equilibrium with its lactonized congener canrenone. Since over 80% of administered spironolactone is irreversibly converted to canrenone/canrenoic acid, its much higher anti‐androgen activity on radioreceptor assay and bioassay may point to the generation of unidentified, minor metabolites with very high affinity for androgen receptors and/or a very long plasma half‐life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MENARD, R. H., STRIPP, B., & GILLETTE, J. R. (1974) · Endocrinology · doi:10.1210/endo-94-6-1628 · Cited by 117
Cited by
Spironolactone in the treatment of polycystic ovary syndrome
Armanini, D., Andrisani, A., Bordin, L., & Sabbadin, C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1215430 · Cited by 53
Self-citationAldosterone receptor blockers spironolactone and canrenone: Two multivalent drugs
Armanini, D., Sabbadin, C., Donà, G., Clari, G., & Bordin, L. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.896901 · Cited by 41
“These antiandrogen effects, particularly in male patients, have limited the use of SP in patients with hypertension and therefore a lot of studies have been performed in order to find some derivative with lower antiandrogen activity [8].”
BackgroundSelf-citationSpironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI
Sabbadin, C., Andrisani, A., Zermiani, M., Donà, G., Bordin, L., Ragazzi, E., Boscaro, M., Ambrosini, G., & Armanini, D. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0466-0 · Cited by 33
“The main active metabolite of SP is canrenone, which is more selective for MR than for AR; therefore the antiandrogenic effect is linked to other metabolites of SP with different antimineralocorticoid and/or antiandrogenic activity [1].”
BackgroundSelf-citationAldosterone in gynecology and its involvement on the risk of hypertension in pregnancy
Sabbadin, C., Andrisani, A., Ambrosini, G., Bordin, L., Donà, G., Manso, J., Ceccato, F., Scaroni, C., & Armanini, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00575 · Cited by 22
Self-citation
Metadata
- Authors
- ARMANINI, D., KARBOWIAK, I., GOI, A., MANTERO, F., & FUNDER, J. W.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 1985-10
- Volume
- 23
- Issue
- 4
- Pages
- 341-347
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2058509711
- Cited by
- 29
- References
- 1
- FWCI
- 0.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IN‐VIVO METABOLITES OF SPIRONOLACTONE AND POTASSIUM CANRENOATE: DETERMINATION OF POTENTIAL ANTI‐ANDROGENIC ACTIVITY BY A MOUSE KIDNEY CYTOSOL RECEPTOR ASSAY. https://app.cochat.ai/papers/10.1111/j.1365-2265.1985.tb01090.x
- The paper
- ARMANINI, D., KARBOWIAK, I., GOI, A., MANTERO, F., & FUNDER, J. W. (1985). IN‐VIVO METABOLITES OF SPIRONOLACTONE AND POTASSIUM CANRENOATE: DETERMINATION OF POTENTIAL ANTI‐ANDROGENIC ACTIVITY BY A MOUSE KIDNEY CYTOSOL RECEPTOR ASSAY. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.1985.tb01090.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.